Abaloparatide (Tymlos)

FDA-approved context Muscle & Bone Health 3 sources

Abaloparatide is a synthetic peptide analog of parathyroid hormone-related protein (PTHrP) that acts as an anabolic agent for bone. Research and clinical trials demonstrate its ability to significantly increase bone mineral density and reduce the risk of fractures in osteoporotic patients.

01Dosing reference

Amount

80 mcg

Frequency

Once daily

Cycle

Up to 2 years maximum lifetime duration

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

PTH1 Receptor Binding

Abaloparatide binds selectively to the parathyroid hormone 1 receptor (PTH1R) on osteoblasts and osteocytes.

Transient Activation

It induces a transient activation of the Gs/cAMP signaling pathway, which favors bone formation over bone resorption.

Anabolic Bone Growth

This targeted activation stimulates osteoblast activity, leading to a net increase in bone mass, architecture, and strength.

03Human evidence

Significant reduction in fracture risk

In the Phase 3 ACTIVE trial involving postmenopausal women with osteoporosis, abaloparatide significantly reduced the incidence of new vertebral and nonvertebral fractures compared to placebo.

Increased bone mineral density (BMD)

Clinical studies show rapid and substantial increases in BMD at the lumbar spine, total hip, and femoral neck over 18 months of treatment.

04Preclinical evidence

Enhanced bone mass and microarchitecture

Studies in ovariectomized rats and monkeys demonstrated that abaloparatide administration restored bone mass and improved trabecular and cortical bone microarchitecture.

Biomechanical strength improvement

Animal models showed that the newly formed bone had normal quality and exhibited increased biomechanical strength without inducing hypercalcemia at therapeutic doses.

05What is known vs. unknown

Reasonably established

FDA-approved for the treatment of osteoporosis in postmenopausal women at high risk for fracture.
Acts as a potent anabolic (bone-building) agent rather than just an antiresorptive medication.
Administered via a daily subcutaneous injection.
Demonstrates a favorable 'anabolic window' by stimulating bone formation more than bone resorption.

Unknowns & limits

The maximum recommended lifetime duration of treatment is typically limited to 2 years due to theoretical risks.
Long-term safety beyond the 2-year treatment window remains an area of ongoing observation.
Optimal sequencing of abaloparatide with antiresorptive agents (like bisphosphonates) is still being refined in clinical practice.

06Safety & regulatory context

Regulatory statusAbaloparatide is an FDA-approved prescription medication (brand name Tymlos). It historically carried a warning regarding a potential risk of osteosarcoma based on high-dose rat studies, limiting lifetime use to two years, though regulatory perspectives on this class are evolving. Common side effects include hypercalcemia (elevated blood calcium), dizziness, nausea, headache, and palpitations. It is contraindicated in patients with a history of skeletal malignancies, bone metastases, or metabolic bone diseases other than osteoporosis.

07Compared with Teriparatide (Forteo)

Abaloparatide (Tymlos) vs. Teriparatide (Forteo)

Key difference

Abaloparatide is a PTHrP analog that binds more transiently to the PTH1 receptor's RG conformation compared to teriparatide (a PTH analog), resulting in less stimulation of bone resorption and a potentially lower risk of hypercalcemia.

When researchers discuss each

Researchers discuss teriparatide as the first-generation anabolic PTH analog, while abaloparatide is discussed as a next-generation option designed to maximize bone formation while minimizing resorptive side effects.

08Glossary

Osteoblast

A cell that secretes the matrix for bone formation.

Osteoclast

A type of bone cell that breaks down bone tissue, a process known as bone resorption.

Anabolic Window

The period or mechanism where bone formation is stimulated to a greater extent than bone resorption, leading to net bone gain.

PTH1R

Parathyroid hormone 1 receptor, a protein on bone cells that regulates calcium homeostasis and bone turnover.

09Knowledge check

Q1What is the primary mechanism of action for abaloparatide?

Q2Why is abaloparatide often compared favorably to teriparatide in terms of its mechanism?

Q3Which interpretation best matches the dossier's documented limitation regarding abaloparatide's long-term use?

Q4According to the dossier, what is the stated clinical implication of abaloparatide's more transient binding to the PTH1 receptor compared with teriparatide?

Q5Which of the following patient histories is explicitly listed in the dossier as a contraindication to abaloparatide?

10Sources

More in Muscle & Bone Health

See all

IGF-1 LR3

Muscle & Bone Health

Early human

IGF-1 LR3 is a synthetic, modified version of Insulin-like Growth Factor-1 with an extended half-life and increased potency. Research highlights its ability to promote muscle cell hyperplasia (growth of new muscle cells), enhance protein synthesis, and improve recovery by resisting deactivation by IGF-binding proteins.

20-50 mcg per day

GDF-8 Myostatin Inhibitor

Muscle & Bone Health

Early human

GDF-8 (Growth Differentiation Factor 8), commonly known as myostatin, is a protein that naturally inhibits muscle growth. Myostatin inhibitors are compounds designed to block this protein, thereby promoting significant muscle hypertrophy and preventing muscle wasting in various research models.

1 mg - 3 mg (highly variable depending on specific peptide/antibody)

ACE-031

Muscle & Bone Health

Early human

ACE-031 is an investigational protein therapeutic designed to build muscle and increase strength by inhibiting signaling through the activin receptor type IIB (ActRIIB). Research primarily focused on its potential to treat muscle-wasting diseases like Duchenne muscular dystrophy, though clinical trials were halted due to safety concerns involving bleeding.

1-3 mg/kg (in clinical trial settings)

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.